Systemic Therapy in Early HER2+ Breast Cancer: More Benefit w/Neoadjuvant Trastuzumab/Pertuzumab/Docetaxel Therapy, Adjuvant Trastuzumab Improves DFS and OS
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Cagatay Arslan
By
Xth Eurasian Hematology-Oncology Congress
FEATURING
Cagatay Arslan
Comments 0
Login to view comments.
Click here to Login